Vetergesic Multidose, 0.3mg/ml, Solution for Injection for Dogs and Cats
Active ingredient: Buprenorphine
Form
Injection
Species
Manufacturer
Ceva Sante Animale
VMD MA No.
14966/3028
What it's used for
Potentiation of the sedative effects of centrally-acting agents. Cats Post-operative analgesia.
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Buprenorphine
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Vetergesic Multidose, 0.3mg/ml, Solution for Injection for Dogs and Cats — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
Cats
Post-operative analgesia.
Species1.1.1 ROUTE OF
ADMINISTRATION
1.1.2 POST-
OPERATIVE
ANALGESIA
1.1.3 POTENTIATION OF
SEDATION
DogsIntramuscular or
intravenous injection
10-20 µg per kg
(0.3-0.6 ml per 10
kg).
For further pain
relief, repeat if
necessary after 3-4
hours with 10 µg
per kg or 5-6 hours
with 20 µg per kg.
10-20 µg per kg (0.3-0.6 ml
per 10 kg).
CatsIntramuscular or
intravenous injection
10 – 20 µg per kg
(0.3 – 0.6 ml per 10
kg), repeated if
necessary, once,
after 1-2 hours.
---
While sedative effects are present by 15 minutes after administration, analgesic
activity becomes apparent after approximately 30 minutes. To ensure that analgesia
is present during surgery and immediately on recovery, the veterinary medicinal
product should be administered pre-operatively as part of premedication.
When administered for potentiation of sedation or as part of premedication, the dose
of other centrally-acting agents, such as acepromazine or medetomidine, should be
reduced. The reduction will depend on the degree of sedation required, the individual
animal, the type of other agents included in premedication and how anaesthesia is to
be induced and maintained. It may also be possible to reduce the amount of
inhalational anaesthetic used.
Animals administered opioids possessing sedative and analgesic properties may show
variable responses. Therefore, the response of individual animals should be monitored
and subsequent doses should be adjusted accordingly. In some cases, repeat doses
may fail to provide additional analgesia. In these cases, consideration should be given
to using a suitable injectable NSAID.
An appropriately graduated syringe must be used to allow accurate dosing.
Do not use pre-operatively for caesarean section (see Section 3.7).
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Rare
(1 to 10 animals / 10,000
animals treated):
Hypertension, Tachycardia
Sedation
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Injection site pain, Local discomfort
Vocalisation
Undetermined frequency
(cannot be estimated from the
available data):
Increased salivation
Bradycardia
Hypothermia, Dehydration
Agitation
Miosis
Respiratory depression
When used to provide analgesia
Resulting from injection site pain or local discomfort
Cats:
Common
(1 to 10 animals / 100 animals
treated):
Mydriasis and signs of euphoria (excessive
purring, pacing, rubbing)
Rare
(1 to 10 animals / 10,000
animals treated):
Sedation
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Injection site pain, Local discomfort
Vocalisation
Undetermined frequency
(cannot be estimated from the
available data):
Respiratory depression
Usually resolve within 24 hours.
When used to provide analgesia
Resulting from injection site pain or local discomfort
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Special precautions for safe use in the target species
Buprenorphine may cause respiratory depression and as with other opioid drugs, care
should be taken when treating animals with impaired respiratory function or animals
that are receiving drugs that can cause respiratory depression.
In case of renal, cardiac or hepatic dysfunction or shock, there may be greater risk
associated with the use of the veterinary medicinal product. The benefit-risk
assessment for using the veterinary medicinal product should be made by the
attending veterinarian. Safety has not been fully evaluated in clinically compromised
cats.
Buprenorphine should be used with caution in animals with impaired liver function,
especially biliary tract disease, as the substance is metabolised by the liver and its
intensity and duration of action may be affected in such animals.
The safety of buprenorphine has not been demonstrated in animals less than 7 weeks
of age, therefore, use in such animals should be based on the benefit-risk assessment
of the veterinarian.
Repeat administration earlier than the recommended repeat interval suggested in
Section 3.9 is not recommended.
Long-term safety of buprenorphine in cats has not been investigated beyond 5
consecutive days of administration.
The effect of an opioid on head injury is dependent on the type and severity of the
injury and the respiratory support supplied. The veterinary medicinal product should
be used in accordance with the benefit-risk assessment of the attending veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Wash hands/affected area thoroughly after any accidental spillage.
As buprenorphine has opioid-like activity, care should be taken to avoid self-injection.
In case of accidental self-injection or ingestion, seek medical advice immediately and
show the package leaflet or the label to the physician.
Following eye contamination or skin contact, wash thoroughly with cold running water.
Seek medical advice if irritation persists.
Special precautions for the protection of the environment
Not applicable.
centrally-acting agents, including tranquillisers, sedatives and hypnotics.
There is evidence in humans to indicate that therapeutic doses of buprenorphine do
not reduce the analgesic efficacy of standard doses of an opioid agonist, and that
when buprenorphine is employed within the normal therapeutic range, standard doses
of opioid agonist may be administered before the effects of the former have ended
without compromising analgesia. However, it is recommended that buprenorphine is
not used in conjunction with morphine or other opioid-type analgesics, e.g. etorphine,
fentanyl, pethidine, methadone, papaveretum or butorphanol.
Buprenorphine has been used with acepromazine, alphaxalone/alphadalone,
atropine, dexmedetomidine, halothane, isoflurane, ketamine, medetomidine, propofol,
sevoflurane, thiopentone and xylazine. When used in combination with sedatives,
depressive effects on heart rate and respiration may be augmented.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Other Products Containing Buprenorphine
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Bupaq 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VVetViva Richter GmbH
Bupaq Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VVetViva Richter GmbH
Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VEcuphar NV
Buprecare Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VEcuphar NV
Buprecord 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VLabiana Life Sciences SA
Buprecord 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VLabiana Life Sciences SA
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
Petlibro Automatic Feeder
Smart automatic pet feeder with app control. Schedule meals, portion control, and feeding history.
We may earn a small commission if you purchase through these links, at no extra cost to you.
Related Medications
Alvegesic Vet. 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VButorphanol
Alvegesic Vet. 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VButorphanol
Bupaq 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
Bupaq Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
Buprecare Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.